Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of 18F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag.
Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.
Molecular Oncology
Viteri, Santiago S; Minchom, Anna A; Bazhenova, Lyudmila L; Ou, Sai-Hong Ignatius SI; Bauml, Joshua M JM; Shell, Scott A SA; Schaffer, Michael M; Gu, Junchen J; Rose, Jennifer B JB; Curtin, Joshua C JC; Mahadevia, Parthiv P; Girard, Nicolas N
First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
Jama Oncology
Zhou, Caicun C; Ramalingam, Suresh S SS; Kim, Tae Min TM; Kim, Sang-We SW; Yang, James Chih-Hsin JC; Riely, Gregory J GJ; Mekhail, Tarek T; Nguyen, Danny D; Garcia Campelo, Maria R MR; Felip, Enriqueta E; Vincent, Sylvie S; Jin, Shu S; Griffin, Celina C; Bunn, Veronica V; Lin, Jianchang J; Lin, Huamao M HM; Mehta, Minal M; Jänne, Pasi A PA
A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses.
Cancers
Koopman, Bart B; Cajiao Garcia, Betzabel N BN; Kuijpers, Chantal C H J CCHJ; Damhuis, Ronald A M RAM; van der Wekken, Anthonie J AJ; Groen, Harry J M HJM; Schuuring, Ed E; Willems, Stefan M SM; van Kempen, Léon C LC
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Nature Medicine
Robichaux, Jacqulyne P JP; Elamin, Yasir Y YY; Tan, Zhi Z; Carter, Brett W BW; Zhang, Shuxing S; Liu, Shengwu S; Li, Shuai S; Chen, Ting T; Poteete, Alissa A; Estrada-Bernal, Adriana A; Le, Anh T AT; Truini, Anna A; Nilsson, Monique B MB; Sun, Huiying H; Roarty, Emily E; Goldberg, Sarah B SB; Brahmer, Julie R JR; Altan, Mehmet M; Lu, Charles C; Papadimitrakopoulou, Vassiliki V; Politi, Katerina K; Doebele, Robert C RC; Wong, Kwok-Kin KK; Heymach, John V JV
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Cancer Research
Kosaka, Takayuki T; Tanizaki, Junko J; Paranal, Raymond M RM; Endoh, Hideki H; Lydon, Christine C; Capelletti, Marzia M; Repellin, Claire E CE; Choi, Jihyun J; Ogino, Atsuko A; Calles, Antonio A; Ercan, Dalia D; Redig, Amanda J AJ; Bahcall, Magda M; Oxnard, Geoffrey R GR; Eck, Michael J MJ; Jänne, Pasi A PA
Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer
Oxnard, Geoffrey R GR; Lo, Peter C PC; Nishino, Mizuki M; Dahlberg, Suzanne E SE; Lindeman, Neal I NI; Butaney, Mohit M; Jackman, David M DM; Johnson, Bruce E BE; Jänne, Pasi A PA
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Jänne, Pasi A PA; Boss, David S DS; Camidge, D Ross DR; Britten, Carolyn D CD; Engelman, Jeffrey A JA; Garon, Edward B EB; Guo, Feng F; Wong, Steven S; Liang, Jane J; Letrent, Stephen S; Millham, Robert R; Taylor, Ian I; Eckhardt, S Gail SG; Schellens, Jan H M JH